<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40511773</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1073</EndPage><MedlinePgn>1062-1073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003833</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Seventeen medical centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with IBD undergoing colectomy and/or proctectomy were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Chemoprophylaxis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thirty-day venous thromboembolism (clot) rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome ( p = 0.0005) and extended resections ( p &lt; 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively ( p &lt; 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge ( p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The limitations to this study were generalizability and selection bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract .</AbstractText><AbstractText Label="PATRONES DE PRCTICA, RESULTADOS Y ESTRATIFICACIN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGA POR ENFERMEDAD INFLAMATORIA INTESTINAL ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRRGICA SOBRE EII" NlmCategory="UNASSIGNED">ANTECEDENTES:No se ha definido la estrategia &#xf3;ptima de quimioprofilaxis de la tromboembolia venosa tras la cirug&#xed;a por enfermedad inflamatoria intestinal.OBJETIVO:Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirug&#xed;a por enfermedad inflamatoria intestinal en una cohorte retrospectiva.DISE&#xd1;O:Entre julio de 2020 y octubre de 2023, la Colaboraci&#xf3;n sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica.ENTORNO:Diecisiete centros m&#xe9;dicos.PACIENTES:Pacientes con enfermedad inflamatoria intestinal sometidos a colectom&#xed;a y/o proctectom&#xed;a.INTERVENCIONES:Quimioprofilaxis.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de tromboembolia venosa (co&#xe1;gulos) a 30 d&#xed;as.RESULTADOS:Durante tres a&#xf1;os, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un co&#xe1;gulo en un plazo de 30 d&#xed;as: el 50 % antes y despu&#xe9;s del alta, respectivamente. Los co&#xe1;gulos se diagnosticaron una mediana de 9 d&#xed;as despu&#xe9;s de la operaci&#xf3;n. Los co&#xe1;gulos m&#xe1;s frecuentes fueron portomesent&#xe9;ricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utiliz&#xf3; una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorr&#xe1;gicas. El an&#xe1;lisis multivariable revel&#xf3; que el s&#xed;ndrome de respuesta inflamatoria sist&#xe9;mica preoperatoria ( p = 0.0005) y las resecciones extendidas ( p &lt; 0.0001) eran factores de riesgo independientes para los co&#xe1;gulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de co&#xe1;gulos del 1.2 %, 4.0 % y 13.5 %, respectivamente ( p &lt; 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoci&#xf3; de forma independiente con un menor riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta ( p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de co&#xe1;gulos del 2.5 %, el n&#xfa;mero estimado de pacientes que deb&#xed;an recibir tratamiento con enoxaparina durante la hospitalizaci&#xf3;n y despu&#xe9;s del alta fue de 54 y 55, respectivamente.LIMITACIONES:Generalizaci&#xf3;n; sesgo de selecci&#xf3;n.CONCLUSIONES:Tras la cirug&#xed;a por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoci&#xf3; con una disminuci&#xf3;n del riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta. Los pacientes con mayor riesgo pueden beneficiarse m&#xe1;s de una quimioprofilaxis prolongada. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-2549-9042</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2646-0625</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California, San Diego School of Medicine, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0003-3418-6774</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Colorectal Surgery Program, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-9138-186</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla F</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-9526-0643</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0382-880</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8273-9471</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krane</LastName><ForeName>Mukta K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-4872-1061</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Washington Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5814-3915</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-4010-5275</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Health, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NSQIP IBD Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Colectomy</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Direct oral anticoagulants</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ileoanal pouch</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Proctectomy</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Anzlovar</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batten</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belding-Schmitt</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohne</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Leon</LastName><ForeName>Elmer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devaney</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divino</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germaine</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyette</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilbert</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirbe</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyke</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaitov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunitake</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavryk</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messaris</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Reba</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narsule</LastName><ForeName>Chaitan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prachand</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenkranz</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Randolph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strong</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylla</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Anila</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Valora</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaska</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torbela</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerian</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whyte</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40511773</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003833</ArticleId><ArticleId IdType="pii">00003453-990000000-00977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation></Reference><Reference><Citation>GamalEldin M, DeHaan RK, Sklow B, et al. Portomesenteric venous thrombosis after colorectal surgery for inflammatory bowel disease: a call to action? [ASCRS abstract POD232]. Dis Colon Rectum. 2021;64:e109&#x2013;e364.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Cima RR, Habermann EB. Timing and location of venous thromboembolisms after surgery for inflammatory bowel disease. J Surg Res. 2024;296:563&#x2013;570.</Citation></Reference><Reference><Citation>Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138&#x2013;1144.</Citation></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, et al.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975&#x2013;980.</Citation></Reference><Reference><Citation>Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2018;61:14&#x2013;20.</Citation></Reference><Reference><Citation>Eisenstein S, Holubar SD, Hilbert N, et al. The ACS National Surgical Quality Improvement Program-Inflammatory Bowel Disease Collaborative: design, implementation, and validation of a disease-specific module. Inflamm Bowel Dis. 2019;25:1731&#x2013;1739.</Citation></Reference><Reference><Citation>Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: a national surgical quality improvement program database study. Dis Colon Rectum. 2015;58:782&#x2013;791.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do patients with inflammatory bowel disease have a higher postoperative risk of venous thromboembolism or do they undergo more high-risk operations? Ann Surg. 2020;271:325&#x2013;331.</Citation></Reference><Reference><Citation>Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(suppl 3):304&#x2013;312.</Citation></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632&#x2013;634.</Citation></Reference><Reference><Citation>Benlice C, Holubar SD, Gorgun E, et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis Colon Rectum. 2018;61:1170&#x2013;1179.</Citation></Reference><Reference><Citation>Cheong JY, Connelly TM, Russell T, et al. Venous thromboembolism risk stratification for patients undergoing surgery for IBD using a novel six factor scoring system using NSQIP-IBD registry. ANZ J Surg. 2023;93:1620&#x2013;1625.</Citation></Reference><Reference><Citation>Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433&#x2013;436.</Citation></Reference><Reference><Citation>Montero Ruiz E, Baldominos Utrilla G, L&#xf3;pez &#xc1;lvarez J, Santolaya Perrin R. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thromb Res. 2011;128:440&#x2013;445.</Citation></Reference><Reference><Citation>Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422&#x2013;1430.</Citation></Reference><Reference><Citation>Lee CHA, Jia X, Lipman JM, et al. Defining the economic burden of perioperative venous thromboembolism in inflammatory bowel disease in the United States. Dis Colon Rectum. 2021;64:871&#x2013;880.</Citation></Reference><Reference><Citation>Leeds IL, DiBrito SR, Canner JK, Haut ER, Safar B. Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn&#x2019;s disease. Dis Colon Rectum. 2019;62:1371&#x2013;1380.</Citation></Reference><Reference><Citation>Leeds IL, Haut ER. Are we really supposed to start giving venous thromboembolism prophylaxis for a month after outpatient surgery? JAMA Surg. 2019;154:1133.</Citation></Reference><Reference><Citation>Prien C, Ribakow D, Steele SR, et al. What about patient cost? Defining copay and out-of-pocket costs of extended venous thromboembolism chemoprophylaxis after colorectal surgery. J Gastrointest Surg. 2023;27:152&#x2013;154.</Citation></Reference><Reference><Citation>Stewart KT, Jafari H, Pattillo J, et al. Avoiding the needle: a quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024;188:131&#x2013;139.</Citation></Reference><Reference><Citation>Ogilvie JW Jr, Khan MT, Hayakawa E, Parker J, Luchtefeld MA. Low-dose rivaroxaban as extended prophylaxis reduces postdischarge venous thromboembolism in patients with malignancy and IBD. Dis Colon Rectum. 2024;67:457&#x2013;465.</Citation></Reference><Reference><Citation>Holubar SD, Eisenstein S, Bordeianou L, et al. Venous thromboembolism prophylaxis practice patterns, outcomes, and risk stratification after surgery for inflammatory bowel disease: a NSQIP IBD Collaborative study. Dis Colon Rectum. 2025;68:e228&#x2013;e229.</Citation></Reference><Reference><Citation>Cordova-Cassia C, Wong D, Cotter MB, Cataldo TE, Poylin VY. Patient&#x2019;s compliance is a contributor to failure of extended antithrombotic prophylaxis in colorectal surgery: prospective cohort study. Surg Endosc. 2022;36:267&#x2013;273.</Citation></Reference><Reference><Citation>Elzaafarany A, Tawfik A, Igbekele T, Day A. EP-351 Extended VTE prophylaxis in patients undergoing elective surgery for colorectal cancer in a district general hospital and its compliance with NICE guidelines. Br J Surg. 2022;109(Suppl 5):znac245.091.</Citation></Reference><Reference><Citation>Yeung T, Ng S, Sidhu R, Ali M. 463 Adherence to extended venous thromboembolism prophylaxis for post operative resection of colorectal malignancies. Br J Surg. 2023;110(Suppl 7):znad258.105.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39508462</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up.</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>208</EndPage><MedlinePgn>199-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003477</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The potential oncological benefit of extending the waiting period between neoadjuvant radiochemotherapy and surgical resection for rectal cancer is debated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the impact of prolonging this waiting period on the 5-year oncological prognosis and 2-year functional result of locally advanced rectal adenocarcinoma.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Phase III, multicenter, randomized, open-label, parallel-group, controlled trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Patients were enrolled from 24 colorectal centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with nonmetastatic mid or lower cT3/T4Nx or cTxN+ rectal adenocarcinoma who had received radiochemotherapy (45-50 Gy radiation dose with fluorouracil or capecitabine).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were randomly assigned to undergo total mesorectal excision either 7 weeks or 11 weeks after radiochemotherapy.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES" NlmCategory="METHODS">Overall survival and disease-free survival at 5-year follow-up and low anterior resection syndrome score assessed after 2 years of follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 265 patients enrolled, 133 were randomized in the 7-week group and 132 in the 11-week group. Twelve patients were excluded because they did not undergo resection. Among 253 patients analyzed, 5-year overall survival was not different between the 2 groups (81.6% in the 7-week group vs 82.6% in the 11-week group, p = 0.827), and neither was the 5-year disease-free survival (70.4% in the 7-week group vs 69.5% in the 11-week group, p = 0.856). No difference was observed between the 2 groups for distant recurrence (27.4% in the 7-week group vs 25.7% in the 11-week group, p = 0.777) or local recurrence (8.4% in the 7-week group vs 10.2% in the 11-week group, p = 0.543). The low anterior resection syndrome score was similar between the 7-week (25.0; interquartile range, 15.0-34.0) and 11-week groups (23.0; interquartile range, 14.2-32.0; p = 0.743).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The response rate to the low anterior resection syndrome questionnaire was only 52%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extending the waiting period between radiochemotherapy and resection from 7 to 11 weeks does not change the 5-year oncological prognosis in rectal cancer or the 2-year low anterior resection occurrence. See Video Abstract.</AbstractText><AbstractText Label="RESULTADOS FINALES DEL ENSAYO GRECCAR SOBRE EL PERODO DE ESPERA TRAS LA RADIOQUIMIOTERAPIA NEOADYUVANTE PARA EL CNCER DE RECTO LOCALMENTE AVANZADO AOS DE SEGUIMIENTO" NlmCategory="UNASSIGNED">ANTECEDENTES:Se debate el posible beneficio oncol&#xf3;gico de prolongar el periodo de espera entre la radioquimioterapia neoadyuvante y la resecci&#xf3;n quir&#xfa;rgica del c&#xe1;ncer de recto.OBJETIVO:Evaluar el impacto de la prolongaci&#xf3;n de este periodo de espera sobre el pron&#xf3;stico oncol&#xf3;gico a 5 a&#xf1;os y el resultado funcional a 2 a&#xf1;os del adenocarcinoma rectal localmente avanzado.DISE&#xd1;O:Ensayo controlado de fase III, multic&#xe9;ntrico, aleatorizado, abierto, de grupos paralelos.LUGAR:Se reclutaron pacientes de 24 centros colorrectales.PACIENTES:Pacientes con adenocarcinoma rectal de tercio medio o inferior, no metast&#xe1;sico cT3-4 o TxN+ que hab&#xed;an recibido radioquimioterapia (45 a 50 Gy con fluorouracilo o capecitabina).INTERVENCI&#xd3;N:Se asignaron aleatoriamente a los pacientes para ser sometidos a una escisi&#xf3;n mesorrectal total 7 semanas (W7) u 11 semanas (W11) despu&#xe9;s de la radioquimioterapia.MEDIDAS DE RESULTADOS PRINCIPALES:Supervivencia global y supervivencia libre de enfermedad a los 5 a&#xf1;os de seguimiento y puntuaci&#xf3;n del s&#xed;ndrome de resecci&#xf3;n anterior baja evaluada a los 2 a&#xf1;os de seguimiento.RESULTADOS:De los 265 pacientes reclutados, 133 fueron asignados aleatoriamente al grupo de 7 semanas y 132 al grupo de 11 semanas. Doce pacientes fueron excluidos porque no fueron sometidos a resecci&#xf3;n. Entre los 253 pacientes analizados, la supervivencia global a 5 a&#xf1;os no fue diferente entre los dos grupos (81,6% en el grupo de 7 semanas frente a 82,6% en el grupo de 11 semanas, p = 0,827), as&#xed; como para la supervivencia libre de enfermedad a 5 a&#xf1;os (70,4% en el grupo de 7 semanas frente a 69,5% en el grupo de 11 semanas, p = 0,856). No se observaron diferencias entre los dos grupos en cuanto a la recidiva a distancia (27,4% en el grupo de 7 semanas frente a 25,7% en el grupo de 11 semanas, p = 0,777) o la recidiva local (8,4% en el grupo de 7 semanas frente a 10,2% en el grupo de 11 semanas, p = 0,543). La puntuaci&#xf3;n del s&#xed;ndrome de resecci&#xf3;n anterior baja fue similar entre los grupos de 7 semanas (25,0 IQR [15,0-34,0]) y 11 semanas (23,0 IQR [14,2-32,0], p = 0,743).LIMITACIONES:La tasa de respuesta al cuestionario LARS fue s&#xf3;lo del 52%.CONCLUSIONES:Ampliar el periodo de espera entre radioquimioterapia y resecci&#xf3;n de 7 a 11 semanas no modifica el pron&#xf3;stico oncol&#xf3;gico a 5 a&#xf1;os en c&#xe1;ncer de recto ni la baja incidencia de resecci&#xf3;n anterior a 2 a&#xf1;os. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collard</LastName><ForeName>Maxime K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, F-75012, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mineur</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oncology, Radiotherapy, Sainte-Camille Institut, Avignon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nekrouf</LastName><ForeName>C&#xe9;lia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital St Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denost</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Bordeaux Colorectal Institute, Clinique Tivoli-Ducos, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouanet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oncological Surgery, Val d'Aurelle Institut, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Chaisemartin</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncological Surgery, Paoli-Calmettes Institut, Marseille CHU, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merdrignac</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Digestive Surgery, CHU, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafari</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncological Surgery, Oscar Lambret Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotte</LastName><ForeName>Eddy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU Lyon-Sud, Pierre-B&#xe9;nite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desrame</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastrology and Hepatology, Jean Mermoz Institut, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manceau</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Digestive and Hepatobiliary Surgery, CHU Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoist</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Digestive and Oncological Surgery, CHU Bic&#xe8;tre, Le Kremlin-Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buscail</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, CHU Purpan, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karoui</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive, Oncological and General Surgery, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panis</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Colorectal Center, Groupe Hospitalier priv&#xe9; Ambroise Par&#xe9;-Hartmann, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piessen</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHRU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saudemont</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery and Transplant Surgery, CHRU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudhomme</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive and Oncological Surgery, CHU Car&#xe9;meau, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peschaud</LastName><ForeName>Fr&#xe9;d&#xe9;rique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU Ambroise-Par&#xe9;, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU Estaing, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loriau</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, St-Joseph Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuech</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duchalais</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU H&#xf4;tel-Dieu, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupinacci</LastName><ForeName>Renato M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of General and Endocrine Surgery, Piti&#xe9; Salp&#xea;tri&#xe8;re Hospital, APHP, Sorbonne University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goasguen</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Croix Saint-Simon Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Tabassome</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital St Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parc</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, F-75012, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefevre</LastName><ForeName>J&#xe9;r&#xe9;mie H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, F-75012, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Research Group of Rectal Cancer Surgery (GRECCAR)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PHRCN 2011, AOM 11314</GrantID><Agency>French Ministry of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6804DJ8Z9U</RegistryNumber><NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="Y">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>14</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39508462</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003477</ArticleId><ArticleId IdType="pii">00003453-990000000-00788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926&#x2013;1933.</Citation></Reference><Reference><Citation>Lakkis Z, Manceau G, Bridoux V, et al.; French Research Group of Rectal Cancer Surgery (GRECCAR) and the French National Society of Coloproctology (SNFCP). Management of rectal cancer: the 2016 French guidelines. Colorectal Dis. 2017;19:115&#x2013;122.</Citation></Reference><Reference><Citation>van Gijn W, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575&#x2013;582.</Citation></Reference><Reference><Citation>Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72:99&#x2013;107.</Citation></Reference><Reference><Citation>Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835&#x2013;844.</Citation></Reference><Reference><Citation>Collard MK, Rullier E, Panis Y, et al.; GRECCAR Group. Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: lessons from a retrospective multicentric cohort of 383 patients. Surgery. 2022;171:1193&#x2013;1199.</Citation></Reference><Reference><Citation>Loria A, Tejani MA, Temple LK, et al. Practice patterns for organ preservation in US patients with rectal cancer, 2006-2020. JAMA Oncol. 2024;10:79&#x2013;86.</Citation></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019;62:802&#x2013;808.</Citation></Reference><Reference><Citation>Ryan EJ, O&#x2019;Sullivan DP, Kelly ME, et al. Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer. Br J Surg. 2019;106:1298&#x2013;1310.</Citation></Reference><Reference><Citation>Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263:458&#x2013;464.</Citation></Reference><Reference><Citation>Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E; French Research Group of Rectal Cancer Surgery (GRECCAR). A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC Cancer. 2013;13:417.</Citation></Reference><Reference><Citation>Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773&#x2013;3780.</Citation></Reference><Reference><Citation>Yu M, Wang DC, Li S, Huang LY, Wei J. Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses. Int J Colorectal Dis. 2022;37:855&#x2013;868.</Citation></Reference><Reference><Citation>Cheng YK, Qin QY, Huang XY, et al. Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. Cancer Med. 2020;9:912&#x2013;919.</Citation></Reference><Reference><Citation>Lef&#xe8;vre JH, Mineur L, Cachanado M, et al.; The French Research Group of Rectal Cancer Surgery (GRECCAR). Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer? Three years&#x2019; follow-up results of the greccar-6 randomized multicenter trial. Ann Surg. 2019;270:747&#x2013;754.</Citation></Reference><Reference><Citation>Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922&#x2013;928.</Citation></Reference><Reference><Citation>Mihmanli M, Kabul G&#xfc;rbulak E, Akg&#xfc;n IE, et al. Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer. World J Gastrointest Oncol. 2016;8:695&#x2013;706.</Citation></Reference><Reference><Citation>Maliske S, Chau J, Ginader T, et al. Timing of surgery following neoadjuvant chemoradiation in rectal cancer: a retrospective analysis from an academic medical center. J Gastrointest Oncol. 2019;10:597&#x2013;604.</Citation></Reference><Reference><Citation>Akgun E, Caliskan C, Bozbiyik O, et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2018;105:1417&#x2013;1425.</Citation></Reference><Reference><Citation>Akgun E, Caliskan C, Bozbiyik O, et al. Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. BJS Open. 2022;6:zrac107.</Citation></Reference><Reference><Citation>Nougaret S, Castan F, de Forges H, et al.; GRECCAR Study Group. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial. Br J Surg. 2019;106:1530&#x2013;1541.</Citation></Reference><Reference><Citation>Niu S, Chen Y, Peng F, et al. The role of MRI after neochemoradiotherapy in predicting pathological tumor regression grade and clinical outcome in patients with locally advanced rectal adenocarcinoma. Front Oncol. 2023;13:1118518.</Citation></Reference><Reference><Citation>Deidda S, Elmore U, Rosati R, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 2021;156:1141&#x2013;1149.</Citation></Reference><Reference><Citation>Jang JK, Choi SH, Park SH, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy. Eur Radiol. 2020;30:2312&#x2013;2323.</Citation></Reference><Reference><Citation>He S, Zhang J, Wang R, et al. Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and stoma status in rectal cancer: long-term functional follow-up of a randomized clinical trial. BJS Open. 2022;6:zrac127.</Citation></Reference><Reference><Citation>Dijkstra EA, Nilsson PJ, Hospers GAP, et al.; Collaborative Investigators. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278:e766&#x2013;e772.</Citation></Reference><Reference><Citation>Meyer VM, Meuzelaar RR, Schoenaker Y, et al. Delayed surgery after neoadjuvant treatment for rectal cancer does not lead to impaired quality of life, worry for cancer, or regret. Cancers (Basel). 2021;13:742.</Citation></Reference><Reference><Citation>Varghese C, Wells CI, O&#x2019;Grady G, Christensen P, Bissett IP, Keane C; on behalf of the Longitudinal LARS Group. The longitudinal course of low-anterior resection syndrome: an individual patient meta-analysis. Ann Surg. 2022;276:46&#x2013;54.</Citation></Reference><Reference><Citation>Conroy T, Bosset JF, Etienne PL, et al.; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702&#x2013;715.</Citation></Reference><Reference><Citation>Schrag D, Shi Q, Weiser MR, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322&#x2013;334.</Citation></Reference><Reference><Citation>Lefevre J, Collard M, Mineur L, et al. Finals results of the GRECCAR-6 trial on waiting period following neo-adjuvant radio-chemotherapy for advanced rectal cancer: 5 years follow-up [ASCRS abstract SS05]. Dis Colon Rectum. 2024;67:e435&#x2013;e436.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38852778</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Common questions and rationale answers about the intestinal bacterial overgrowth syndrome (SIBO).</ArticleTitle><Pagination><StartPage>502216</StartPage><MedlinePgn>502216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2024.502216</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(24)00198-5</ELocationID><Abstract><AbstractText>The recognition and treatment of intestinal bacterial overgrowth syndrome are matters of controversy. The symptoms that have guided the search for the disorder suffer from lack of specificity, especially in the absence of well-defined predisposing factors. The accuracy of diagnostic procedures has been questioned and the proposed therapies achieve generally low effectiveness figures, with large differences between available studies. It is also unknown whether the normalization of tests is really a guarantee of cure. Within this framework of uncertainty, and in order to contribute to the guidance and homogenization of medical practice, a group of experts from the AEG and ASENEM have formulated the key questions on the management of this pathology and have provided answers to them, in accordance with the available scientific evidence. In addition, they have drawn up statements based on the conclusions of the review and have voted on them individually to reflect the degree of consensus for each statement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alcedo Gonz&#xe1;lez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Instituto de Investigaci&#xf3;n Sanitaria (IIS) Arag&#xf3;n, Zaragoza, Espa&#xf1;a. Electronic address: jalcedo@telefonica.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estremera-Ar&#xe9;valo</LastName><ForeName>Ferm&#xed;n</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario de Navarra, Navarrabiomed, Universidad P&#xfa;blica de Navarra - IdiSNA, Navarra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobi&#xe1;n Malaver</LastName><ForeName>Julyssa</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de Enfermedades Digestivas, Policl&#xed;nica Guipuzkoa, San Sebasti&#xe1;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos Vicente</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratorio de Neuro-Inmuno-Gastroenterolog&#xed;a, Unidad de Investigaci&#xf3;n de Aparato Digestivo, Institut de Recerca (VHIR), Servicio de Aparato Digestivo, Hospital Universitario Vall d'Hebron, Barcelona, Espa&#xf1;a; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (Ciberehd), Instituto de Salud Carlos III, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcal&#xe1;-Gonz&#xe1;lez</LastName><ForeName>Luis Gerardo</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Aparato Digestivo, Hospital Universitario Vall d'Hebron, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naves</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital del Mar, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barba Orozco</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad de Neurogastroenterolog&#xed;a y Motilidad, Hospital Cl&#xed;nic de Barcelona, Barcelona, Espa&#xf1;a; Departamento de Gastroenterolog&#xed;a, Universidad de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber Caselles</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Aparato Digestivo, Hospital Universitario Vall d'Hebron, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano-Falc&#xf3;n</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario Virgen de las Nieves, Granada, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Accarino Garaventa</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Consulta de Gastroenterolog&#xed;a, Hospital HM Delfos, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-Cotoner</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratorio de Neuro-Inmuno-Gastroenterolog&#xed;a, Unidad de Investigaci&#xf3;n de Aparato Digestivo, Institut de Recerca (VHIR), Servicio de Aparato Digestivo, Hospital Universitario Vall d'Hebron, Barcelona, Espa&#xf1;a; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (Ciberehd), Instituto de Salud Carlos III, Madrid, Espa&#xf1;a; Facultad de Medicina, Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serra Pueyo</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (Ciberehd), Instituto de Salud Carlos III, Madrid, Espa&#xf1;a; &#xc1;rea de Aparato Digestivo, Hospital Universitario Vall d'Hebron, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Preguntas comunes y respuestas razonadas sobre el s&#xed;ndrome del sobrecrecimiento bacteriano intestinal (SIBO).</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001765" MajorTopicYN="Y">Blind Loop Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012196" MajorTopicYN="N">Review Literature as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal distension</Keyword><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">Antibi&#xf3;ticos</Keyword><Keyword MajorTopicYN="N">Bloating</Keyword><Keyword MajorTopicYN="N">Cultivo de aspirado intestinal</Keyword><Keyword MajorTopicYN="N">Diarrea</Keyword><Keyword MajorTopicYN="N">Diarrhea</Keyword><Keyword MajorTopicYN="N">Distensi&#xf3;n abdominal</Keyword><Keyword MajorTopicYN="N">Hinchaz&#xf3;n</Keyword><Keyword MajorTopicYN="N">Hydrogen and methane test</Keyword><Keyword MajorTopicYN="N">Iifaximin</Keyword><Keyword MajorTopicYN="N">Iifaximina</Keyword><Keyword MajorTopicYN="N">Intestinal aspirate culture</Keyword><Keyword MajorTopicYN="N">Intestinal bacterial overgrowth</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Probi&#xf3;ticos</Keyword><Keyword MajorTopicYN="N">SIBO</Keyword><Keyword MajorTopicYN="N">Sobrecrecimiento bacteriano intestinal</Keyword><Keyword MajorTopicYN="N">Test de hidr&#xf3;geno y metano</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>9</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38852778</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2024.502216</ArticleId><ArticleId IdType="pii">S0210-5705(24)00198-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38588497</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>[Authors' reply to the letter "Guillain-Barr&#xe9; syndrome before and during the COVID-19 pandemic"].</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>214</EndPage><MedlinePgn>213-214</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.M24000872</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez-Hern&#xe1;ndez</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica de Enfermedades Neuromusculares, Instituto Nacional de Neurolog&#xed;a y Neurocirug&#xed;a "Dr. Manuel Velasco Su&#xe1;rez", Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Urgencias, Instituto Nacional de Neurolog&#xed;a y Neurocirug&#xed;a "Dr. Manuel Velasco Su&#xe1;rez", Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galnares-Olalde</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Instituto Nacional de Neurolog&#xed;a y Neurocirug&#xed;a "Dr. Manuel Velasco Su&#xe1;rez", Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Ca&#xf1;as</LastName><ForeName>Edwin S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica de Enfermedades Neuromusculares, Instituto Nacional de Neurolog&#xed;a y Neurocirug&#xed;a "Dr. Manuel Velasco Su&#xe1;rez", Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><VernacularTitle>Respuesta de los autores a la carta &#x201c;S&#xed;ndrome de Guillain-Barr&#xe9; antes y durante la pandemia de COVID-19&#x201d;.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>16</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38588497</ArticleId><ArticleId IdType="doi">10.24875/GMM.M24000872</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36441832</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of a Symptom-Based Scoring System for Bowel Dysfunction After Ileoanal Pouch Reconstruction: The Ileoanal Pouch Syndrome Severity Score.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>96</EndPage><MedlinePgn>87-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002663</ELocationID><Abstract><AbstractText Label="BACKGROUND">The Patient-Reported Outcomes After Pouch Surgery Delphi Consensus Study identified 7 symptoms and 7 consequences as key domains for evaluating and analyzing ileoanal pouch function.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to use items identified as priorities by the Patient-Reported Outcomes After Pouch Surgery Delphi Consensus Study to create a validated tool for quantifying pouch function.</AbstractText><AbstractText Label="DESIGN">Patients were administered a questionnaire-based survey eliciting responses regarding frequency of a variety of bowel symptoms.</AbstractText><AbstractText Label="SETTING">Patients with pouches were recruited at IBD centers and via patient advocacy websites.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Associations between items and quality of life were computed in a score generation cohort of 298 patients by logistic regression modeling. Individual score values were designated to items to create an additive score titled the Ileoanal Pouch Syndrome Severity Score. Validity was tested in a subsequent cohort of 386 patients using receiver operating characteristic area under the curve. In addition, test-retest validity, convergent validity, and clinical validity were evaluated.</AbstractText><AbstractText Label="RESULTS">After the determination of item weights, the range of possible scores was found to be 0 to 145. Score ranges were then determined as cutoff values for "ileoanal pouch syndrome." The score was then validated on the second patient cohort, with a receiver operating characteristic area under the curve of 0.83. Importantly, worsening severity of Ileoanal Pouch Syndrome Score significantly correlated with higher rates of poor quality of life. Finally, the questionnaire was rigorously validated to show test-retest validity, convergent validity compared to other bowel function scores, and clinical validity.</AbstractText><AbstractText Label="CONCLUSIONS">This study developed a patient-centered, clinically useful scoring system that can quantify the range and severity of symptoms experienced by patients with ileoanal pouches and their correlation with quality of life.</AbstractText><AbstractText Label="DESARROLLO Y VALIDACIN DE UN SISTEMA DE PUNTUACIN BASADO EN SNTOMAS PARA LA DISFUNCIN INTESTINAL DESPUS DE LA RECONSTRUCCIN CON RESERVORIO ILEOANAL LA PUNTUACIN DE GRAVEDAD DEL SNDROME DE RESERVORIO ILEOANAL">ANTECEDENTES:En el estudio Delphi Consensus los resultados informados por el paciente despu&#xe9;s de la cirug&#xed;a de reservorio identificaron 7 s&#xed;ntomas y 7 consecuencias como dominios clave para evaluar y analizar la funci&#xf3;n del reservorio ileoanal.OBJETIVO:Utilizar elementos identificados como prioritarios por el estudio de consenso Delphi de resultados informados por el paciente despu&#xe9;s de la cirug&#xed;a de reservorio para crear una herramienta validada para cuantificar la funci&#xf3;n del reservorio.DISE&#xd1;O:A los pacientes se les administr&#xf3; una encuesta basada en un cuestionario que obtuvo respuestas con respecto a la frecuencia de una variedad de s&#xed;ntomas intestinales.ESCENARIO:Los pacientes con reservorio fueron reclutados en centros de enfermedad inflamatoria intestinal y a trav&#xe9;s de sitios web dirigidos al paciente.PRINCIPALES MEDIDAS DE RESULTADO:Las asociaciones entre los elementos y la calidad de vida se calcularon en una cohorte de generaci&#xf3;n de puntuaci&#xf3;n de 298 pacientes mediante un modelo de regresi&#xf3;n log&#xed;stica. Se asignaron valores de puntuaci&#xf3;n individuales a los elementos para crear una puntuaci&#xf3;n aditiva denominada Puntuaci&#xf3;n de gravedad del s&#xed;ndrome de reservorio ileoanal. La validez se prob&#xf3; en una cohorte posterior de 386 pacientes utilizando el &#xe1;rea caracter&#xed;stica operativa del receptor bajo la curva. Adem&#xe1;s, se evaluaron la validez del test-retest, la validez convergente y la validez cl&#xed;nica.RESULTADOS:Despu&#xe9;s de determinar el peso de los elementos, el rango de puntajes posibles fue de 0 a 145. Los rangos de puntaje se determinaron luego como valores de corte para el "s&#xed;ndrome de la reservorio ileoanal". A continuaci&#xf3;n, la puntuaci&#xf3;n se valid&#xf3; en la segunda cohorte de pacientes, con un &#xe1;rea caracter&#xed;stica operativa del receptor bajo la curva de 0.3. Es importante destacar que el empeoramiento de la gravedad de la puntuaci&#xf3;n del s&#xed;ndrome de reservorio ileoanal se correlacion&#xf3; significativamente con tasas m&#xe1;s altas de mala calidad de vida. Por &#xfa;ltimo, el cuestionario fue rigurosamente validado para mostrar validez test-retest, validez convergente en comparaci&#xf3;n con otras puntuaciones de funci&#xf3;n intestinal y validez cl&#xed;nica.CONCLUSIONES:Este estudio desarroll&#xf3; un sistema de puntuaci&#xf3;n cl&#xed;nicamente &#xfa;til y centrado en el paciente que puede cuantificar el rango y la gravedad de los s&#xed;ntomas experimentados por los pacientes con reservorio ileoanal y su correlaci&#xf3;n con la calidad de vida. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cavallaro</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastrointestinal and Oncologic Surgery, Section of Colon and Rectal Surgery, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PROPS Scientific Committee</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2023 Aug 1;66(8):e849. doi: 10.1097/DCR.0000000000002958.</RefSource><PMID Version="1">37482427</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039021" MajorTopicYN="Y">Colonic Pouches</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007410" MajorTopicYN="Y">Intestinal Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>28</Day><Hour>14</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36441832</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002663</ArticleId><ArticleId IdType="pii">00003453-202301000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Geltzeiler CB, Lu KC, Diggs BS, et al. Initial surgical management of ulcerative colitis in the biologic era. Dis Colon Rectum. 2014;57:1358&#x2013;1363.</Citation></Reference><Reference><Citation>Lee GC, Cavallaro PM, Savitt LR, et al. Bowel function after J-pouch may be more complex than previously appreciated: a comprehensive analysis to highlight existing knowledge gaps. Dis Colon Rectum. 2020;63:207&#x2013;216.</Citation></Reference><Reference><Citation>Lightner AL, Steele SR, McMichael JP, et al. Pouch function over time and with advancing age. Dis Colon Rectum. 2022;65:254&#x2013;263.</Citation></Reference><Reference><Citation>Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679&#x2013;685.</Citation></Reference><Reference><Citation>Simillis C, Afxentiou T, Pellino G, et al. A systematic review and meta-analysis comparing adverse events and functional outcomes of different pouch designs after restorative proctocolectomy. Colorectal Dis. 2018;20:664&#x2013;675.</Citation></Reference><Reference><Citation>Brandsborg S, Chen TY, Nicholls RJ, Laurberg S. Difference between patients&#x2019; and clinicians&#x2019; perception of pouch dysfunction and its impact on quality of life following restorative proctocolectomy. Colorectal Dis. 2015;17:O136&#x2013;O140.</Citation></Reference><Reference><Citation>Cavallaro P, Fearnhead N, Bissett I, et al.; PROPS Delphi Study Expert Panels. Patients undergoing ileoanal pouch surgery experience a constellation of symptoms and consequences representing a unique syndrome: a report from the Patient-Reported Outcomes after Pouch Surgery (PROPS) Delphi Consensus Study. Ann Surg. 2021;274:138&#x2013;145.</Citation></Reference><Reference><Citation>Cavallaro PM, Fearnhead NS, Bissett IP, et al.; PROPS Delphi Study Expert Panels. Patients undergoing ileoanal pouch surgery experience a constellation of symptoms and consequences representing a unique syndrome: a report from the Patient-Reported Outcomes after Pouch Surgery (PROPS) Delphi Consensus Study. Dis Colon Rectum. 2021;64:861&#x2013;870.</Citation></Reference><Reference><Citation>Long MD, Kappelman MD, Martin CF, et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis. 2012;18:2099&#x2013;2106.</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)&#x2014;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2013;381.</Citation></Reference><Reference><Citation>Jorge JMN, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77&#x2013;97.</Citation></Reference><Reference><Citation>Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut. 1999;44:77&#x2013;80.</Citation></Reference><Reference><Citation>Temple LK, Bacik J, Savatta SG, et al. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum. 2005;48:1353&#x2013;1365.</Citation></Reference><Reference><Citation>Hicks CW, Hodin RA, Savitt L, Bordeianou L. Does intramesorectal proctectomy with rectal eversion affect postoperative complications compared to standard total mesorectal excision in patients with ulcerative colitis? J Gastrointest Surg. 2014;18:385&#x2013;390.</Citation></Reference><Reference><Citation>Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000;43:9&#x2013;16.</Citation></Reference><Reference><Citation>Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922&#x2013;928.</Citation></Reference><Reference><Citation>Kappelman MD, Long MD, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1315&#x2013;1323.e2.</Citation></Reference><Reference><Citation>Kochar B, Martin CF, Kappelman MD, et al. Evaluation of gastrointestinal patient reported outcomes measurement information system (GI-PROMIS) symptom scales in subjects with inflammatory bowel diseases. Am J Gastroenterol. 2018;113:72&#x2013;79.</Citation></Reference><Reference><Citation>Elfeki H, Thy&#xf8; A, Nepogodiev D, et al.; Colostomy Impact Score study group. Patient and healthcare professional perceptions of colostomy-related problems and their impact on quality of life following rectal cancer surgery. BJS Open. 2018;2:336&#x2013;344.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35272309</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectoceles: Is There a Correlation Between Presence of Vaginal Prolapse and Radiographic Findings in Symptomatic Women?</ArticleTitle><Pagination><StartPage>552</StartPage><EndPage>558</EndPage><MedlinePgn>552-558</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Constipation is highly prevalent. Women with constipation are evaluated for the presence of vaginal prolapse that may contribute to obstructed defecation syndrome. Defecography can identify anatomic causes of obstructed defecation syndrome (rectocele, intussusception, and enterocele).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to assess the characteristics of women with obstructed defecation syndrome and radiographic rectoceles with and without posterior vaginal wall prolapse and to characterize the relationship between anatomical abnormalities and dysfunction.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This is a retrospective case-control study of women with obstructed defecation syndrome who had radiographic rectoceles on defecography.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Women who presented to a Pelvic Floor Disorders Center were included.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Cases were defined as constipated women with radiographic rectoceles and at least stage II posterior vaginal wall prolapse on examination. Controls were patients with radiographic rectoceles but without posterior vaginal wall prolapse on examination.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Patient characteristics, anorectal testing results, and validated questionnaires were compared between groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 106 women met inclusion criteria. Women with posterior vaginal wall prolapse (48 (45.3%)) had larger rectoceles on defecography than women without it on examination (3.4 cm vs 3.0 cm, p &lt; 0.01). Women with posterior vaginal wall prolapse on examination were more likely to splint during defecation than women without vaginal wall prolapse (63.8% vs 27.3%, p &lt; 0.01). All other defecatory symptoms, anorectal manometry parameters, and questionnaire responses were similar between groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study was limited by its retrospective study design. Our data were taken from a single institution within a center specializing in the treatment of pelvic floor disorders, potentially limiting generalizability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with constipation, radiographic rectoceles, and vaginal prolapse may differ from those without evidence of prolapse. Patients with vaginal prolapse were more likely to splint to aide evacuation and demonstrated larger rectoceles on defecography. Further studies are needed to determine whether constipation causes progression along this continuum or whether progression of prolapse is a cause of worsening defecatory dysfunction. See Video Abstract at http://links.lww.com/DCR/B626.</AbstractText><AbstractText Label="RECTOCELES EXISTE UNA CORRELACIN ENTRE LA PRESENCIA DE PROLAPSO VAGINAL Y LOS HALLAZGOS RADIOLGICOS EN MUJERES SINTOMTICAS" NlmCategory="UNASSIGNED">ANTECEDENTES:El estre&#xf1;imiento es una enfermedad muy prevalente. Las mujeres con estre&#xf1;imiento se eval&#xfa;an para detectar la presencia de prolapso vaginal que pueda contribuir al s&#xed;ndrome de defecaci&#xf3;n obstructiva. La defecograf&#xed;a puede identificar las causas anat&#xf3;micas del s&#xed;ndrome de defecaci&#xf3;n obstructiva (rectocele, invaginaci&#xf3;n intestinal (intususcepci&#xf3;n) y enterocele).OBJETIVO:Este estudio tiene como objetivo evaluar las caracter&#xed;sticas de las mujeres con s&#xed;ndrome de defecaci&#xf3;n obstructiva y la presencia de rectocele como hallazgo radiol&#xf3;gico, con y sin prolapso de la pared vaginal posterior, y caracterizar la relaci&#xf3;n entre las anomal&#xed;as anat&#xf3;micas y la presencia de disfunci&#xf3;n.DISE&#xd1;O:Este es un estudio retrospectivo de casos y controles, de mujeres con s&#xed;ndrome de defecaci&#xf3;n obstructiva, que ten&#xed;an rectocele como hallazgo radiol&#xf3;gico en una defecograf&#xed;a.MARCO:Mujeres que acudieron a un Centro de Trastornos del Piso P&#xe9;lvico.PACIENTES:Los casos fueron definidos como mujeres con estre&#xf1;imiento con hallazgos radiol&#xf3;gicos de rectocele, con al menos un prolapso estadio II de la pared vaginal posterio, en el examen f&#xed;sico. Los controles fueron pacientes con solo rectocele por hallazgos radiol&#xf3;gicos, sin prolapso de la pared vaginal posterior en el examen f&#xed;sico.PRINCIPALES MEDIDAS DE RESULTADO:Se compararon entre los grupos: las caracter&#xed;sticas de las pacientes, los resultados de las pruebas diagn&#xf3;sticas anorrectales y los cuestionarios validados.RESULTADOS:Un total de 106 mujeres cumplieron los criterios de inclusi&#xf3;n. Las mujeres con prolapso de la pared vaginal posterior 48 (45,3%) ten&#xed;an rectoceles de mayor tama&#xf1;o en la defecograf&#xed;a en comparaci&#xf3;n con las mujeres sin rectocele en el examen f&#xed;sico (3,4&#x2009;cm versus 3,0&#x2009;cm, p &lt;0,01). Las mujeres con prolapso de la pared vaginal posterior en el examen, ten&#xed;an una mayor probabilidad de que les fuera necesario ejercer una maniobra de presi&#xf3;n manual o digital del perin&#xe9; durante la defecaci&#xf3;n, comparado con las mujeres sin rectocele cl&#xed;nico (63,8% versus 27,3%, p &lt;0,01). Todos los dem&#xe1;s s&#xed;ntomas defecatorios, los par&#xe1;metros de la manometr&#xed;a anorrectal, y las respuestas al cuestionario fueron similares entre los grupos.LIMITACIONES:Estudio retrospectivo. Los datos fueron obtenidos de la base de datos de un centro especializado en el tratamiento de los trastornos del piso p&#xe9;lvico lo que potencialmente limita generalizar.CONCLUSIONES:Las pacientes con estre&#xf1;imiento, rectocele como hallazgo radiol&#xf3;gico, y prolapso vaginal pueden ser diferentes de aquellas sin evidencia de prolapso. Las pacientes con prolapso vaginal, ten&#xed;an una mayor probabilidad de que les fuera necesario ejercer maniobras manuales o digitales de presi&#xf3;n a nivel del perin&#xe9; para ayudar a la evacuaci&#xf3;n, y ten&#xed;an rectoceles de mayor tama&#xf1;o en la defecograf&#xed;a. Se necesitan m&#xe1;s estudios para determinar si el estre&#xf1;imiento causa que el rectocele aumente progresivamente de tama&#xf1;o, empeorando la disfunci&#xf3;n defecatoria. Consulte Video Resumen en http://links.lww.com/DCR/B626.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Marcus V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Vincent Obstetrics, Gynecology and Reproductive Biology, Division of Female Pelvic Medicine and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Angel M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Greater Boston Urology, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janmey</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Magee-Women's Hospital, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foust-Wright</LastName><ForeName>Caroline E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Magee-Women's Hospital, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulliam</LastName><ForeName>Samantha J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Renovia Inc, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savitt</LastName><ForeName>Lieba R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Division of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Division of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Milena M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Vincent Obstetrics, Gynecology and Reproductive Biology, Division of Female Pelvic Medicine and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059952" MajorTopicYN="Y">Pelvic Floor Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020047" MajorTopicYN="N">Rectocele</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014596" MajorTopicYN="Y">Uterine Prolapse</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35272309</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002015</ArticleId><ArticleId IdType="pii">00003453-202204000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Foxx-Orenstein AE, McNally MA, Odunsi ST. Update on constipation: one treatment does not fit all. Cleve Clin J Med. 2008;75:813&#x2013;824.</Citation></Reference><Reference><Citation>Paquette IM, Varma M, Ternent C, et al. The American Society of Colon and Rectal Surgeons&#x2019; clinical practice guideline for the evaluation and management of constipation. Dis Colon Rectum. 2016;59:479&#x2013;492.</Citation></Reference><Reference><Citation>Ridgeway BM, Weinstein MM, Tunitsky-Bitton E. American Urogynecologic Society best-practice statement on evaluation of obstructed defecation. Female Pelvic Med Reconstr Surg. 2018;24:383&#x2013;391.</Citation></Reference><Reference><Citation>Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750&#x2013;759.</Citation></Reference><Reference><Citation>Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377&#x2013;1390.</Citation></Reference><Reference><Citation>Khaikin M, Wexner SD. Treatment strategies in obstructed defecation and fecal incontinence. World J Gastroenterol. 2006;12:3168&#x2013;3173.</Citation></Reference><Reference><Citation>Faccioli N, Comai A, Mainardi P, Perandini S, Moore F, Pozzi-Mucelli R. Defecography: a practical approach. Diagn Interv Radiol. 2010;16:209&#x2013;216.</Citation></Reference><Reference><Citation>Shorvon PJ, McHugh S, Diamant NE, Somers S, Stevenson GW. Defecography in normal volunteers: results and implications. Gut. 1989;30:1737&#x2013;1749.</Citation></Reference><Reference><Citation>Committee on Practice Bulletins-Gynecology, American Urogynecologic Society. Practice Bulletin No. 185: pelvic organ prolapse. Obstet Gynecol. 2017;130:e234&#x2013;e250.</Citation></Reference><Reference><Citation>Bump RC, Mattiasson A, B&#xf8; K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175:10&#x2013;17.</Citation></Reference><Reference><Citation>Hale DS, Fenner D. Consistently inconsistent, the posterior vaginal wall. Am J Obstet Gynecol. 2016;214:314&#x2013;320.</Citation></Reference><Reference><Citation>Burrows LJ, Meyn LA, Walters MD, Weber AM. Pelvic symptoms in women with pelvic organ prolapse. Obstet Gynecol. 2004;104(5 pt 1):982&#x2013;988.</Citation></Reference><Reference><Citation>Fialkow MF, Gardella C, Melville J, Lentz GM, Fenner DE. Posterior vaginal wall defects and their relation to measures of pelvic floor neuromuscular function and posterior compartment symptoms. Am J Obstet Gynecol. 2002;187:1443&#x2013;1448.</Citation></Reference><Reference><Citation>Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144:218&#x2013;238.</Citation></Reference><Reference><Citation>Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Contin ence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5&#x2013;26.</Citation></Reference><Reference><Citation>Varma MG, Wang JY, Berian JR, Patterson TR, McCrea GL, Hart SL. The constipation severity instrument: a validated measure. Dis Colon Rectum. 2008;51:162&#x2013;172.</Citation></Reference><Reference><Citation>Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn. 1995;14:131&#x2013;139.</Citation></Reference><Reference><Citation>Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol. 2005;193:103&#x2013;113.</Citation></Reference><Reference><Citation>Johansson C, Ihre T, Holmstr&#xf6;m B, Nordstr&#xf6;m E, Dolk A, Brod&#xe9;n G. A combined electromyographic and cineradiologic investigation in patients with defecation disorders. Dis Colon Rectum. 1990;33:1009&#x2013;1013.</Citation></Reference><Reference><Citation>Bordeianou LG, Carmichael JC, Paquette IM, et al. Consensus Statement of definitions for anorectal physiology testing and pelvic floor terminology (revised). Dis Colon Rectum. 2018;61:421&#x2013;427.</Citation></Reference><Reference><Citation>Bordeianou L, Savitt L, Dursun A. Measurements of pelvic floor dyssynergia: which test result matters? Dis Colon Rectum. 2011;54:60&#x2013;65.</Citation></Reference><Reference><Citation>Wallace SL, Torosis M, Rogo-Gupta L. Does rectocele on defecography equate to rectocele on physical examination in patients with defecatory symptoms? Female Pelvic Med Reconstr Surg. 2021;27:18&#x2013;22.</Citation></Reference><Reference><Citation>Hai-Ying C, Guzm&#xe1;n Rojas R, Hall JC, Atan IK, Dietz HP. Digitation associated with defecation: what does it mean in urogynaecological patients? Int Urogynecol J. 2016;27:229&#x2013;232.</Citation></Reference><Reference><Citation>Hicks CW, Weinstein M, Wakamatsu M, Savitt L, Pulliam S, Bordeianou L. In patients with rectoceles and obstructed defecation syndrome, surgery should be the option of last resort. Surgery. 2014;155:659&#x2013;667.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>